+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric Cancer Therapy Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4591665
  • Report
  • May 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Celltrion Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Imugene Limited
  • MORE
The Gastric Cancer Therapy Market is expected to register a CAGR of 15.8% during the forecast period. Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world.

The high mortality rates are primarily caused by the late diagnosis of the disease, with patients often missing the opportunity for a surgical cure, and cancer already having been developed into an advanced stage when identified.

Gastric cancer is a common cancer, found, especially in the developing economies of Eastern Asia, Middle and Eastern Europe, and South America. Cases of gastric cancer in China account for 44.2% of the new gastric cancer cases, globally.

According to the estimates of GLOBOCAN 2018, the number of incident cases of stomach cancer in Asia in 2018 was about 769,728 and it is expected to increase to 947,186 by 2025. Although chemotherapy can improve chances of survival for patients with advanced gastric cancer, the overall survival rate is still very low. A significant number of studies have shown that molecular targeted therapy can further improve the survival rates of patients suffering from gastric cancer.

Recently, chemotherapeutic agents, such as pembrolizumab and ramucirumab, have been used for the treatment of gastric cancer. Due to the increasing number of molecular studies of gastric cancers, new molecular targeted drugs have entered into clinical use. For example, Trastuzumab, an antibody targeting the human epidermal growth factor receptor 2 (HER2), can significantly improve the survival rates of advanced gastric cancer patients.

Thus, the rising incidences of the stomach cancer is one of the major factors driving the growth of the market.

Key Market Trends

Chemotherapy Segment is Expected to Hold a Major Market Share in the Gastric Cancer Therapy Market
  • Chemotherapy is the most common form of therapeutics used to stop or slow the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, while chemotherapy works throughout the whole body. This means that chemotherapy can kill and damage cancer cells that have spread to other parts of the body, far away from the original tumor.
  • Even though chemotherapy has many associated side effects, it is still the therapy of choice among most oncologists, worldwide. It is also cheap, when compared to immunotherapies, and is administered either through an intravenous route or orally.
  • According to the estimates of GLOBOCAN, in 2018, South Korea had the highest rate of stomach cancer, followed by Mongolia. Additionally, in men the stomach cancer rate in South Korea was 57.8, while in women, it was about 23.5, in 2018.
  • Some of the chemotherapy drugs used in the treatment of stomach cancer are 5-FU, Capecitabine, Carboplatin, Cisplatin, Docetaxel, Epirubicin, Irinotecan, Oxaliplatin, and Paclitaxel.
  • Stomach cancer prevalence is expected to increase in the coming years, and the rising number of cancer cases is driving the chemotherapy segment, which is expected to grow further during the forecast period. Chemotherapy-based drugs have been the choice of treatment for decades, and have been the among the major treatment options for the treatment of several types of cancers. Hence, the market is expected to witness substantial growth during the forecast period.
North America Dominates the Market and Expected to do the Same during the Forecast Period
  • North America is expected to dominate the overall market, throughout the forecast period. In the North American region, the United States holds the largest market share. This is attributed to the rising prevalence of stomach cancer and the availability of advanced technology in cancer research and treatment centers.
  • According to the American Cancer Society’s, estimates that in 2020 approximately 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Moreover, about 11,010 people will die due to gastric cancer (6,650 men and 4,360 women).
  • Furthermore, the region is well-developed, in terms of availability of advanced technologies to treat the cancers, and medical device companies are pushing themselves to compete with the established players across the United States and Canada. Such factors boost the growth of the market in North America.
Competitive Landscape

The gastric cancer therapy market is competitive and consists of a few major players. In terms of share, a few of the major players are currently dominating the market. Some of the major players in the market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Pfizer, Merck & Co. Inc., and Celltrion Inc., among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Celltrion Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Imugene Limited
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Gastric Cancer
4.2.2 Introduction of Novel Therapies for Metastatic Stomach Cancer
4.3 Market Restraints
4.3.1 High Cost of Cancer Therapy and Side Effects of Cancer Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapy Type
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.1.3 Immunotherapy
5.1.4 Radiation Therapy
5.1.5 Surgery
5.2 By End User
5.2.1 Ambulatory Surgery Centers
5.2.2 Hospitals and Specialty Clinics
5.2.3 Other End users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb
6.1.2 Celltrion Inc.
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 GlaxoSmithKline PLC
6.1.6 Imugene Limited
6.1.7 Novartis AG
6.1.8 Merck & Co. Inc.
6.1.9 Otsuka Holdings Co. Ltd
6.1.10 Pfizer Inc.
6.1.11 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bristol-Myers Squibb
  • Celltrion Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Imugene Limited
  • Novartis AG
  • Merck & Co. Inc.
  • Otsuka Holdings Co. Ltd
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll